Tetrandrine inhibits human brain glioblastoma multiforme GBM 8401 cancer cell migration and invasion in vitro.
Anticarcinogenic Agents
/ pharmacology
Benzylisoquinolines
/ pharmacology
Brain Neoplasms
/ metabolism
Cell Line, Tumor
Cell Movement
/ drug effects
Glioblastoma
/ metabolism
Humans
Matrix Metalloproteinase 2
/ metabolism
Matrix Metalloproteinase 9
/ metabolism
NF-kappa B
/ metabolism
Neoplasm Invasiveness
Signal Transduction
GBM 8401 cells
MMP-2
NF-κB
Tetrandrine (TET)
migration and invasion
Journal
Environmental toxicology
ISSN: 1522-7278
Titre abrégé: Environ Toxicol
Pays: United States
ID NLM: 100885357
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
21
06
2018
revised:
19
11
2018
accepted:
24
11
2018
pubmed:
15
12
2018
medline:
23
4
2019
entrez:
15
12
2018
Statut:
ppublish
Résumé
Tetrandrine (TET) has been reported to induce anti-cancer activity in many human cancer cells and also to inhibit cancer cell migration and invasion. However, there are no reports to show TET inhibits cell migration and invasion in human brain glioblastoma multiforme GBM 8401 cells. In this study, we investigated the anti-metastasis effects of TET on GBM 8401 cells in vitro. Under sub-lethal concentrations (from 1, 5 up to 10 μM), TET significantly inhibited cell mobility, migration and invasion of GBM 8401 cells that were assayed by wound healing and Transwell assays. Gelatin zymography assay showed that TET inhibited MMP-2 activity in GBM 8401 cells. Western blotting results indicated that TET inhibited several key metastasis-related proteins, such as p-EGFR
Substances chimiques
Anticarcinogenic Agents
0
Benzylisoquinolines
0
NF-kappa B
0
tetrandrine
29EX23D5AJ
Matrix Metalloproteinase 2
EC 3.4.24.24
Matrix Metalloproteinase 9
EC 3.4.24.35
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
364-374Subventions
Organisme : China Medical University
ID : CMU106-ASIA-01
Organisme : Experiments and data analysis were performed in part through the use of the Medical Research Core Facilities Center, Office of Research & Development at China medical University, Taichung, Taiwan.
Informations de copyright
© 2018 Wiley Periodicals, Inc.